Accolade (NASDAQ:ACCD) Lowered to “Hold” Rating by Stephens

Stephens downgraded shares of Accolade (NASDAQ:ACCD) from a strong-buy rating to a hold rating in a research report released on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Leerink Partnrs lowered Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Truist Financial lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Morgan Stanley dropped their price objective on shares of Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Wells Fargo & Company reduced their target price on shares of Accolade from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Friday, October 11th. Finally, Leerink Partners restated a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Twelve investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $7.55.

Accolade Stock Up 0.1 %

Shares of NASDAQ:ACCD opened at $6.84 on Monday. The company’s fifty day moving average is $3.88 and its two-hundred day moving average is $3.83. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.72 and a current ratio of 2.72. Accolade has a 1-year low of $3.08 and a 1-year high of $13.93. The stock has a market capitalization of $550.87 million, a price-to-earnings ratio of -6.64 and a beta of 2.08.

Accolade (NASDAQ:ACCD) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. Equities analysts anticipate that Accolade will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Rajeev Singh sold 13,357 shares of Accolade stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total transaction of $48,085.20. Following the transaction, the chief executive officer now directly owns 814,316 shares in the company, valued at approximately $2,931,537.60. This trade represents a 1.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 41,962 shares of company stock worth $152,424 over the last ninety days. Company insiders own 8.20% of the company’s stock.

Institutional Trading of Accolade

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers boosted its holdings in Accolade by 22.5% during the second quarter. Rhumbline Advisers now owns 124,351 shares of the company’s stock worth $445,000 after buying an additional 22,857 shares in the last quarter. Blair William & Co. IL lifted its position in shares of Accolade by 73.1% during the 2nd quarter. Blair William & Co. IL now owns 79,834 shares of the company’s stock valued at $286,000 after acquiring an additional 33,725 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Accolade by 64.4% during the 2nd quarter. XTX Topco Ltd now owns 49,454 shares of the company’s stock worth $177,000 after acquiring an additional 19,369 shares in the last quarter. Inspire Investing LLC grew its holdings in shares of Accolade by 179.7% in the 2nd quarter. Inspire Investing LLC now owns 96,021 shares of the company’s stock worth $344,000 after acquiring an additional 61,688 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in Accolade during the 2nd quarter worth about $297,000. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.